ArticleBMC cancer2025
Pre-treatment peripheral blood TCR repertoire as a predictor of response in patients with NSCLC treated with immunochemotherapy.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Serum exosomal miR-192-5p as a novel predictive biomarker for immunochemotherapy response in advanced non-small cell lung cancer.BMC cancer · 2026Article
- Peripheral blood biomarkers in PD-1/PD-L1 immunotherapy: distinguishing predictive from prognostic biomarkers.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundAlthough there has been progress in developing T-cell receptor (TCR)-based biomarkers to predict clinical benefit (CB) in patients treated with immune checkpoint blockade (ICB) therapy, studies on the circulating TCR repertoire in non-small cell lung cancer (NSCLC) remain limited. Therefore, further investigation and validation of the TCR repertoire as a potential biomarker for predicting the benefit of immune checkpoint inhibitor therapy are needed.
methodsBlood samples were collected from patients with advanced NSCLC before initiating anti-programmed cell death 1 (anti-PD-1) antibody treatment in combination with chemotherapy. Next-generation sequencing was used to analyze the complementarity-determining region 3 (CDR3) of the T cell receptor beta (TRB)gene. Richness, Shannon diversity indices, and the usage of variable and joining genes were studied. TCR repertoire metrics were then correlated with CB, progression-free survival (PFS), and overall survival (OS).
resultsWe found that the number of unique clones and richness index were comparable between the clinical benefit (CB) and no-clinical benefit (non-CB) groups. A high number of unique clones and a higher richness index were correlated with clinical benefit among patients treated with chemoimmunotherapy (ChIO) therapy. However, despite this association, a statistically non-significant correlation was observed between any of the TCR repertoire metrics and PFS or OS in patients treated with ChIO. Higher TRBJ2-1 frequencies were associated with clinical benefit. Most clonotypes contained CDR3 fragments ranging from 12 to 16 amino acids in length. However, visualization of the relative similarity of TCR repertoires using multidimensional scaling analysis revealed that TCR repertoires of the benefit group could not be separated from those of the benefit group.
conclusionThe circulating TCR repertoire may serve as a potential tool for predicting clinical outcomes of anti-PD-1 plus chemotherapy, aiding the selection of patients likely to experience clinical benefit. Further large-scale prospective studies are required to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.